Vijukumar Abhishek, Kumar Aryan, Kumar Hardik
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001 India.
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001 India.
Diagn Microbiol Infect Dis. 2025 Mar;111(3):116699. doi: 10.1016/j.diagmicrobio.2025.116699. Epub 2025 Jan 20.
Oropouche virus (OROV), an emerging arbovirus, poses a significant public health challenge in tropical and subtropical regions, with no licensed vaccines or antiviral therapies currently available. This review explores recent advancements in therapeutic strategies and vaccine development for OROV, focusing on molecular mechanisms of viral replication, identification of potential antiviral targets, and the role of immunotherapy in managing infections. Promising antiviral candidates, including ribavirin, mycophenolic acid, and interferon, have demonstrated efficacy in in vitro studies, offering a foundation for further investigation. The challenges of preclinical and clinical development, such as high mutation rates, immune response variability, and vaccine delivery hurdles, are critically analyzed. By addressing the progress and remaining gaps, this article aims to provide a comprehensive overview to inform future research and facilitate the development of effective antiviral strategies and vaccines for OROV.
奥罗普切病毒（OROV）是一种新兴的虫媒病毒，在热带和亚热带地区对公共卫生构成重大挑战，目前尚无获得许可的疫苗或抗病毒疗法。本综述探讨了奥罗普切病毒治疗策略和疫苗开发的最新进展，重点关注病毒复制的分子机制、潜在抗病毒靶点的鉴定以及免疫疗法在控制感染中的作用。包括利巴韦林、霉酚酸和干扰素在内的有前景的抗病毒候选药物在体外研究中已显示出疗效，为进一步研究奠定了基础。对临床前和临床开发的挑战，如高突变率、免疫反应变异性和疫苗递送障碍进行了批判性分析。通过阐述进展和尚存的差距，本文旨在提供全面概述，为未来研究提供参考，并促进奥罗普切病毒有效抗病毒策略和疫苗的开发。
